| Document |
Document Title |
|
WO/2011/015523A1 |
The present invention pertains to Benzyl-substituted tetracyclic heterocyclic compounds, as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 p...
|
|
WO/2011/016472A1 |
Disclosed are: an effective inhibitor of TTK protein kinase; and an effective medicinal agent. Specifically disclosed are: a compound; and inventions relating to the compound (e.g., a pharmaceutical composition, a TTK inhibitor, and othe...
|
|
WO/2011/012674A1 |
The invention relates to benzoindazole derivatives according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
|
|
WO/2011/011843A1 |
A chemical method for sexual sterilisation and libido suppression in male mammals is indicated to achieve the biological sterilisation of male mammals such as bovines, sheep, goats, equines, swine, dogs, cats and humans. The invention co...
|
|
WO/2011/012600A1 |
The invention relates to ring-annulated dihydropyrrolo[2,1-a]isoquinoline compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
|
|
WO/2011/005759A2 |
Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of th...
|
|
WO/2010/150525A1 |
Provided is a method for evaluating urate transport-related disease factor and inflammation-related disease factor, in which a high-capacity urate transporter is identified in order to assist in the early treatment and prevention of urat...
|
|
WO/2010/145010A1 |
Novel methods for reduction or elimination of the incidence of hot flushes, vasomotor symptoms, and night sweats while decreasing the risk of acquiring breast, uterine or endometrial cancer and furthermore having beneficial effect by inh...
|
|
WO/2010/147184A1 |
Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or dysmenorrhea-related conditions. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or dysmenorrhea-related conditions, whic...
|
|
WO/2010/146313A2 |
The invention relates to the use of a composition comprising clamshell mother-of-pearl, and optionally active substances of the water of Cocos nucifera as a nutritive medium that can dilute reproductive cells.
|
|
WO/2010/147234A1 |
To provide a melanin concentrating hormone receptor antagonist useful as medicines for central system disorders, cardiovascular disorders and metabolic disorders. Provided is a compound of a formula (I): wherein R1a and R1b each are a hy...
|
|
WO/2010/147226A1 |
Provided is a compound having a serotonin 5-HT2c receptor activating action, useful for lower urinary tract conditions, obesity and cancer. A compound represented by the formula (I0): wherein each symbol is as defined in the specificatio...
|
|
WO/2010/146310A1 |
The invention relates to a composition comprising clamshell mother-of-pearl for using in the treatment of implantation problems in mammals, especially ovines, bovids and equines.
|
|
WO/2010/146622A1 |
Provided are drugs, external preparations and cosmetics having an effect of inhibiting NFAT signal, an effect of inhibiting calcineurin and an effect of promoting hair growth. An NFAT signal inhibitor which comprises as the active ingred...
|
|
WO/2010/126528A9 |
Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in ne...
|
|
WO/2010/123221A9 |
The present invention relates to a composition for preventing and improving the symptoms of menopause, containing glyceollins as an active ingredient. More particularly, the present invention relates to a composition for preventing and i...
|
|
WO/2010/140926A1 |
The invention relates to a novel agent having an influence on the genital, sexual and reproductive function of mammals and human beings. More specifically, the invention relates to the use of a heptapeptide of the general formula (I) Тh...
|
|
WO/2010/139256A1 |
An adduct formed by a phosphodiesterase inhibitor and isoflavone and its use are disclosed, wherein the weight ratio of said phosphodiesterase-5 inhibitor to the isoflavone substance is 1:100-100:1. The adduct possesses effects for impro...
|
|
WO/2010/138823A1 |
The present disclosure includes compositions and methods of inactivating pathogens of a genital tract of a female. The compositions include L-lactic acid substantially free of D-lactic acid. In particular, an intravaginal ring for sustai...
|
|
WO/2010/137620A1 |
Disclosed is a phenoxyethylamine derivative having an excellent selective α1D adrenergic receptor antagonistic activity. Specifically disclosed is a compound represented by formula (I) [wherein each symbol is as defined in the descripti...
|
|
WO/2010/137350A1 |
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (Ia) or (Ib), a pharmaceutically acceptable salt there...
|
|
WO/2010/137351A1 |
The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tet...
|
|
WO/2010/136438A1 |
The invention relates to imidazoiso[5,1-a]quinoline and 5,6-dihydro-imidazoiso[5,1-a]quinoline derivatives according to general Formula (1) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of inf...
|
|
WO/2010/133761A1 |
The present invention is related to an intravaginal delivery system comprising one or more therapeutically active or a health-promoting substance capable of preventing and/or treating vaginal infections as well as giving protection again...
|
|
WO/2010/133071A1 |
The present invention provides a type of highly purified follicle stimulating hormone from urea, the purity of which is not less than 95w/w%, and the impurity content of which is not more than 5w/w%. And the present invention provides a ...
|
|
WO/2010/134117A1 |
The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility.
|
|
WO/2010/133314A1 |
The present invention relates to a medication for oral administration comprising at least one estrogen and/or one gestagen and at least one probiotic bacterial strain, such as the Lactobacillus species. The medication according to the in...
|
|
WO/2010/134767A2 |
The present invention relates to a pharmaceutical composition for treating uterine myoma, containing, as an active ingredient, the extract of one or more herbs or medicinal materials selected from a group consisting of shady Jerusalem sa...
|
|
WO/2010/126167A1 |
Disclosed are: a compound represented by formula (I), or a salt, solvate or physiologically functional derivative thereof; and a pharmaceutical composition comprising the compound or the salt, solvate or physiologically functional deriva...
|
|
WO/2010/124392A1 |
The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for treating inflammatory conditions.
|
|
WO/2010/125799A1 |
Disclosed is a compound represented by formula (I), which inhibits the action of PI3K, controls a number of biological processes, such as the growth, differentiation, survival, proliferation, migration and metabolism of cells, and, there...
|
|
WO/2010/123243A2 |
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...
|
|
WO/2010/121980A1 |
The present invention is directed to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by Atopobium species. The invention is further directed to the use of nifuratel to treat bacteriuria, uri...
|
|
WO/2010/124085A2 |
The present invention relates to methods and compositions for preventing and treating uterine disease, and in particular to vaccines and bacteriophage compositions for treating or preventing puerperal metritis, clinical endometritis and/...
|
|
WO/2010/120133A2 |
The present invention relates to a phytoestrogen composition for preventing or relieving climacteric or menopausal symptoms, wherein the phytoestrogen composition comprises at least one extract selected from the group consisting of lily,...
|
|
WO/2010/119030A1 |
The invention relates to a method for contraception, which method comprises on-demand administering levonorgestrel or norgestrel in a woman, within 24 hours before an intercourse.
|
|
WO/2010/120764A1 |
A method for a same visit treatment for erectile dysfunction and premature ejaculation. The method includes: performing a diagnostic on the patient using physical conditions of the patient; determining a diagnostic group of the patient, ...
|
|
WO/2010/115318A1 |
A follicle-stimulating hormone(FSH) with high specific activity and preparation method thereof are disclosed, wherein specific activity of the follicle-stimulating hormone is not less than 7000 international unit (IU)/mg protein. The met...
|
|
WO/2010/114105A1 |
Disclosed are: a pharmaceutical composition which comprises a monoclonal antibody having an excellent affinity and an excellent neutralizing ability for human cytomegalovirus (HCMV) (which a virus causing various disease conditions) and ...
|
|
WO/2010/113834A1 |
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...
|
|
WO/2010/114106A1 |
Disclosed are: a pharmaceutical composition which comprises a monoclonal antibody capable of binding specifically to an AD1 region of gB glycoprotein of human cytomegalovirus (HCMV) (which is a virus causing various disease conditions) a...
|
|
WO/2001/079455A9 |
The invention provides isolated nucleic acid and amino acid sequences of Slo potassium family members such as, antibodies to Kv10 subfamily members such as Kv10.1, methods of detecting Kv10, subfamily members such as Kv10.1, methods of s...
|
|
WO/2010/108942A1 |
This invention relates to fertilization modulation compounds and process for implementing them.
|
|
WO/2010/105448A1 |
A Chinese medicinal composition for external use in treatment and health care of renal function and its use in manufacture of cataplasm. The composition is prepared by the following materials in the light of weight parts: Herba Epimedii ...
|
|
WO/2010/104882A1 |
The present invention relates to methods for enhancing mammalian sperm motility, mobility and vitality using calcimimetics.
|
|
WO/2010/104024A1 |
Disclosed is a piperazine compound represented by general formula (I) or a salt thereof. [In the formula, R1 represents an alkyl group having 1 to 6 carbon atoms; R2 represents any one selected from a hydroxy group, an alkyl group having...
|
|
WO/2010/099567A1 |
The present invention relates to a method of increasing litter size in mammals and more particularly relates to a method of increasing litter size in pigs. More particularly, the present invention relates to methods of increasing litter ...
|
|
WO/2010/101968A1 |
Methods for improving ejaculate of a patient in need thereof are presented, more particularly, methods for increasing ejaculate volume/prostatic fluid to increase viability of sperm contained therein by administration of a neurotoxin to ...
|
|
WO/2010/101164A1 |
Disclosed is a novel pyridine derivative which has a good hypoglycemic activity and can treat glucose and lipid metabolic diseases or diseases associated with a peroxisome proliferator-activated receptor (PPAR) γ and/or prevent the onse...
|
|
WO/2010/096854A1 |
The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-3 receptor (MC3R) and / or the melanocortin-4 receptor (MC4R). Compounds of this invention can be used to ...
|
